Prospective Grant of Exclusive License: Conjugate Vaccines To Prevent Diseases Caused by Nontypeable Haemophilus Influenzae and Moraxella Catarrhalis, Particularly Otitis Media

概要

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license concerning the inventions embodied in: U.S. Patent Application Serial Number 08/842,409 (now USPN 6,207,157) entitled "Conjugate vaccine for Nontypeable H. influenzae", its divisional application U. S. Patent Application Serial Number 09/789,017, and U.S. Patent Application Serial Number 60/071,483 (now U.S. Patent Application Serial Number 09/610,034 and PCT/US99/00590, National Staged in Australia, Brazil, Canada, China, Europe, Korea, Mexico, and Japan), entitled "Lipooligosaccharide-Based Vaccine for Prevention of Moraxella (Branhamella) catarrhalis Infections in Humans", to Apovia, Inc., a company of San Diego, California. The United States of America is an assignee to the patent rights of these inventions. The contemplated exclusive license may be limited to the development of vaccines for the prevention or treatment of diseases in humans caused by infection with nontypeable H. influenzae and M. catarrhalis. This notice is a modification to two previous Federal R